Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based technology and
products to the worldwide life sciences industry, recently announced that its
patented pressure cycling technology (“PCT”) platform was featured in 15
independent scientific presentations at the annual conference of the American
Society of Mass Spectrometry (“ASMS”) (http://ibn.fm/vLiCW). An article further discussing the
company reads, “The ASMS annual meeting is a highly reputable conference
attended by more than 10,000 scientists from around the world. It is a showcase
event for new research and scientific findings that has been held every year
since 1953. . . . This year’s PCT-involving presentations spanned a range of
applications — from cancer research to molecular biology and biomarker
discovery. Of the 15 presentations, nine focused on the importance of PBIO’s
PCT platform in cancer research. Three of these presentations put emphasis on
the use of streamlined sample preparation protocols and systems featuring
Pressure BioSciences’ Barocycler 2320EXT instrument and its associated and
proprietary MicroTubes.”
To view the full article, visit http://ibn.fm/0Yf6F
About Pressure BioSciences Inc.
Pressure BioSciences (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control biomolecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics characterization
and quality control, soil and plant biology, forensics and counter-bioterror
applications. Additionally, major new market opportunities have emerged in the
use of its pressure-based technologies in the following areas: (1) the use of
its recently acquired PreEMT technology from BaroFold Inc. to allow entry into
the biologics contract research services sector, and (2) the use of its
recently patented, scalable, high-efficiency, pressure-based Ultra Shear
Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise
immiscible fluids (e.g., oils and water) and (ii) prepare higher quality,
homogenized, extended shelf-life or room temperature stable low-acid liquid
foods that cannot be effectively preserved using existing non-thermal technologies.
For more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
